# Bundesinstitut für Risikobewertung (BfR)

### **Towards a Risk-Analysis of Antibiotic Resistance**

9.-11. November 2003, Berlin

### **Preliminary Programme 21.10.2003**

### **General information for participants**

**Hotel** Best Western

Hotel Steglitz International

Albrechtstraße 2 12165 Berlin

Tel: +49-30-790-05-0 Fax:+49-30-790-055-50

Conference

Bundesinstitut für Risikobewertung

Location

Martin-Lerche-Hörsaal Diedersdorfer Weg 1

12277 Berlin

Tel.: +49-30-8412-2145 Fax.:+49-30-8412-

Conference

**Language** English with simultaneous translation to German.

**Transport** All transport indicated in the programme will be organised by BfR. Please

assemble in the lobby in time.

### **Preliminary programme**

## Sunday 9<sup>th</sup> November 2003

Arrival of participants at Hotel Steglitz International

From 15.00 Registration at:

BfR Dahlem Thielallee 88-92 D-14195 Berlin

Tel.: +49-1888-412-0

Speakers and invited experts are kindly requested to bring their travel documents for reimbursement.

18.00-21.00 Welcome reception with buffet in the BfR Casino (see above)

## Monday 10<sup>th</sup> November 2003

monday 10	November 2000
08.00-09.00	Late registration at BfR Marienfelde, Diedersdorfer Weg 1
08.15	Departure from Hotel Steglitz International to BfR Marienfelde
09.00-09.10	Welcome of the Federal Ministry of Consumer Protection, Food and Agriculture Secretary of State Alexander Müller
09.10-09.20	Welcome and opening by the President of the BfR  Andreas Hensel
09.20-09.30	Introduction and scope of the meeting. Technical remarks Reiner Helmuth
09.30-09.50	Towards a rational risk analysis of antimicrobial resistance David Vose
Session I:	Hazard Identification Chair: JohnThrelfall, Stefan Schwarz
09.50-10.10	Use of antimicrobials in veterinary medicine and food animal production Fritz Ungemach
10.10-10.30	Spread of resistance determinants  Patrice Courvalin
10.30-10.50	Spread of resistant clones - molecular epidemiological approaches  Trudy Wassenaar
10.50-11.00	Discussion

# 11.00-11.30 Coffee break

Session II: Hazard Characterization
Chair: Linda Tollefson, Helmuth Tschäpe

11.30-11.50 Veterinary use of antimicrobials and emergence of resistance in zoonotic and

sentinel organisms in EU countries

Robin Bywater

11.50-12.10	Spread of resistant bacteria and resistance genes from animals to humans Kåre Mølbak
12.10-12.30	Antibiotics triggering local bacterial evolution Fernando Baquero
12.30-12.40	Discussion
12.40-14.00	Lunch break
14.00-14.15	Hazard characterization in practice, examples from human medicine Uwe Frank
14.15-15.00	Examples of contemporary problems:  14.15-14.30 Glycopeptide resistant Staphylococcus, Wolfgang Witte  14.30-14.45 ESBLs, Patrice Nordmann  14.45-15.00 Fluoroquinolones, Fred Angulo
15.00-15.15	Discussion
Session III:	Exposure Assessment Chair: Fred Angulo, Fernando Baquero
15.15-15.30	Consumption of antimicrobial agents in EU, data from IFAH-Europe, Tom Shryock
15.30-16.00	Coffee break
16.00-16.20	Monitoring antimicrobial resistance - Principles and limitations.  Frank Aarestrup
16.20-16.35	Presentations from monitoring programmes and their consequences, USA Paula Fedorka-Cray
16.35-16.50	Presentations from monitoring programmes and their consequences, EU Dik Mevius
16.50-17.00	Short presentations on the situation in Germany: Humans Klaus Huppertz
17.00-17.40	Short presentations on the situation in Germany: Animals 17.00-17.10 Salmonella, <i>Andreas Schroeter</i> 17.10-17.20 Campylobacter, <i>Edda Bartelt</i> 17.20-17.30 Commensals, <i>Lüppo Ellerbroek</i> 17.30-17.40 Animal pathogens, <i>Jürgen Wallmann</i>
17.40-18.00	Discussion
Session IV:	Risk Characterization - Food and Public Health Aspects Chair: Henrik Wegener, Wolfgang Witte
18.00-18.20	Summary of the day along the public health aspects Richard Wise
18.45	Transport to Schloss Diedersdorf
19.30-21.30 21.30 approx.	Dinner in Diedersdorf Transport to hotel

## Tuesday 11<sup>th</sup> November 2003

8.00 Departure from hotel Steglitz International to BfR Marienfelde.

## Session IV (continued): Risk Characterization - Food and Public Health Aspects Chair: Henrik Wegener, Wolfgang Witte

What do we know: Reports on conclusions and activities of previous expert groups

00 00 00 45	
08.30-08.45	Microbial Threat - The Copenhagen Recommendations-Initiative of the EU Chief Medical Officers Niels Frimodt Mfller
08.45-09.00	
09.00-09.15	
09.15-09.30	
09.30-09.45	
09.45-10.00	Discussion
10.00-10.05	Technical remarks for working groups, Reiner Helmuth
10.05-10.30	Coffee break
10.30-12.30	Working in Groups on Session I to IV under Chairmen leaderships
12.30-14.00	Lunch break
Session V:	Management options and measures - What can be done? Chair: Christian Grugel, Andreas Hensel
14.00-14.20	Report from Group I: Hazard Identification
14.00-14.20	John Threlfall, Stefan Schwarz
14.20-14.40	
	John Threlfall, Stefan Schwarz  Report from Group II: Hazard Characterization
14.20-14.40	John Threlfall, Stefan Schwarz  Report from Group II: Hazard Characterization  Linda Tollefson, Helmuth Tschäpe  Report from Group III: Exposure Assessment
14.20-14.40 14.40-15.00	Report from Group II: Hazard Characterization Linda Tollefson, Helmuth Tschäpe  Report from Group III: Exposure Assessment Fred Angulo, Fernando Baquero  Report from Group IV: Risk Characterization
14.20-14.40 14.40-15.00 15.00-15.20	Report from Group II: Hazard Characterization Linda Tollefson, Helmuth Tschäpe  Report from Group III: Exposure Assessment Fred Angulo, Fernando Baquero  Report from Group IV: Risk Characterization Henrik Wegener, Wolfgang Witte  Coffee break  The FDA position
14.20-14.40 14.40-15.00 15.00-15.20 15.20-15.45	Report from Group II: Hazard Characterization Linda Tollefson, Helmuth Tschäpe  Report from Group III: Exposure Assessment Fred Angulo, Fernando Baquero  Report from Group IV: Risk Characterization Henrik Wegener, Wolfgang Witte  Coffee break  The FDA position Linda Tollefson Risk management measures
14.20-14.40 14.40-15.00 15.00-15.20 15.20-15.45 15.45-16.05	Report from Group II: Hazard Characterization Linda Tollefson, Helmuth Tschäpe  Report from Group III: Exposure Assessment Fred Angulo, Fernando Baquero  Report from Group IV: Risk Characterization Henrik Wegener, Wolfgang Witte  Coffee break  The FDA position Linda Tollefson Risk management measures Christian Grugel Alternatives to antimicrobials and perspectives after the meeting
14.20-14.40 14.40-15.00 15.00-15.20 15.20-15.45 15.45-16.05 16.05-16.25	Report from Group II: Hazard Characterization Linda Tollefson, Helmuth Tschäpe  Report from Group III: Exposure Assessment Fred Angulo, Fernando Baquero  Report from Group IV: Risk Characterization Henrik Wegener, Wolfgang Witte  Coffee break  The FDA position Linda Tollefson Risk management measures Christian Grugel